Pathology and Lab Medicine

Episodes 1-16 of 16

• 

  MinuteCE®

  Breaking Barriers in AML: Risk Stratification, Molecular Profiling, and Novel Menin-Directed Treatment Options

  1.00 credit 10 episodes

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Stratifying Risk to Guide Therapy in R/R AML 

  RestartResume

  Stratifying Risk to Guide Therapy in R/R AML 

  MinuteCE®

  Stratifying Risk to Guide Therapy in R/R AML 

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Molecular Profiling as a Cornerstone of Precision AML Therapy

  RestartResume

  Molecular Profiling as a Cornerstone of Precision AML Therapy

  MinuteCE®

  Molecular Profiling as a Cornerstone of Precision AML Therapy

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Menin Inhibitors: Biologic and Clinical Rationale 

  RestartResume

  Menin Inhibitors: Biologic and Clinical Rationale 

  MinuteCE®

  Menin Inhibitors: Biologic and Clinical Rationale 

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML 

  RestartResume

  Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML 

  MinuteCE®

  Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML 

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management

  RestartResume

  Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management

  MinuteCE®

  Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Managing Adverse Events Associated With Menin Inhibitors 

  RestartResume

  Managing Adverse Events Associated With Menin Inhibitors 

  MinuteCE®

  Managing Adverse Events Associated With Menin Inhibitors 

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Applying Evidence to Clinical Practice 

  RestartResume

  Applying Evidence to Clinical Practice 

  MinuteCE®

  Applying Evidence to Clinical Practice 

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Emerging Directions in Menin-Directed AML Therapy 

  RestartResume

  Emerging Directions in Menin-Directed AML Therapy 

  MinuteCE®

  Emerging Directions in Menin-Directed AML Therapy 

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Ongoing Clinical Trials in AML With Menin Inhibitors 

  RestartResume

  Ongoing Clinical Trials in AML With Menin Inhibitors 

  MinuteCE®

  Ongoing Clinical Trials in AML With Menin Inhibitors 

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Expert Recommendations and Key Takeaways

  RestartResume

  Expert Recommendations and Key Takeaways

  MinuteCE®

  Expert Recommendations and Key Takeaways

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  MinuteCE®

  The Pathologist Perspective: Identifying Systemic Mastocytosis in the Community

  0.50 credits 4 episodes

  • 

    

    Nathan A. Boggs, MD

  • 

    

    Tracy George, MD

  • 

    

    Lindsay Rein, MD

  0.50 credits 4 episodes

• 

  RestartResume

  Differential Diagnosis of Indolent Systemic Mastocytosis

  RestartResume

  Differential Diagnosis of Indolent Systemic Mastocytosis

  MinuteCE®

  Differential Diagnosis of Indolent Systemic Mastocytosis

  0.50 program credits

  • 

    

    Nathan A. Boggs, MD

  • 

    

    Tracy George, MD

  • 

    

    Lindsay Rein, MD

  0.50 program credits

• 

  RestartResume

  Is it Nonresponsive/Progressive ISM?

  RestartResume

  Is it Nonresponsive/Progressive ISM?

  MinuteCE®

  Is it Nonresponsive/Progressive ISM?

  0.50 program credits

  • 

    

    Nathan A. Boggs, MD

  • 

    

    Tracy George, MD

  • 

    

    Lindsay Rein, MD

  0.50 program credits

• 

  RestartResume

  Diagnosis and Treatment of Systemic Mastocytosis With an Associated Hematologic Neoplasm

  RestartResume

  Diagnosis and Treatment of Systemic Mastocytosis With an Associated Hematologic Neoplasm

  MinuteCE®

  Diagnosis and Treatment of Systemic Mastocytosis With an Associated Hematologic Neoplasm

  0.50 program credits

  • 

    

    Nathan A. Boggs, MD

  • 

    

    Tracy George, MD

  • 

    

    Lindsay Rein, MD

  0.50 program credits

• 

  RestartResume

  Accurate Diagnosis and Management of Hereditary Alpha Tryptasemia

  RestartResume

  Accurate Diagnosis and Management of Hereditary Alpha Tryptasemia

  MinuteCE®

  Accurate Diagnosis and Management of Hereditary Alpha Tryptasemia

  0.50 program credits

  • 

    

    Nathan A. Boggs, MD

  • 

    

    Tracy George, MD

  • 

    

    Lindsay Rein, MD

  0.50 program credits